Dr. Langan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
94 old short hills road
Suite 1172
Livingston, NJ 07039Phone+1 973-322-5195Fax+1 973-322-2471
Summary
- Russell C. Langan, MD, FACS, FSSO, Associate Chief Surgical Officer for System Integration and Quality and Director of Surgical Oncology, Northern Region, RWJBarnabas Health (RWJBH) and Rutgers Cancer Institute of New Jersey (RCINJ), is responsible for coordinating and expanding high quality cancer surgical services throughout the RWJBH system. He is the Chief of Surgical Oncology and Hepatopancreatobiliary Surgery, the Chairman of the Institutional Review Board (IRB), the Surgical Director of the Comprehensive Liver Center and a member of the Board of Trustees at Cooperman Barnabas Medical Center (CBMC), an RWJBH facility.
He specializes in complex surgical oncology and has a particular interest and expertise in the surgical management of diseases of the liver, pancreas, bile ducts, gallbladder and stomach as well as cancers which have spread to the peritoneum. Additionally, he cares for all benign biliary pathologies.
Dr. Langan and his partners are the highest volume pancreatic surgeons and run the most comprehensive pancreatic program in the state of NJ through RCINJ, the states only National Cancer Institute Designated Comprehensive Cancer Center.
As a member of both the CBMC Cancer Center and the Gastrointestinal/Hepatobiliary Program at the Rutgers Cancer Institute of New Jersey, he works collaboratively with members of the multidisciplinary disease management teams including medical oncologists, radiation oncologists, gastroenterologists, radiologists, pathologists, genetic counselors and dietitians to ensure patients receive the highest level of evidence-based care including clinical trials. At CBMC, he launched a Pancreatic Cyst Screening program to monitor pancreatic lesions which do not merit immediate removal but require observation. Recently, he brought the national, multi-center Alliance Trial for operable pancreas cancer to NJ and is the primary investigator
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2015 - 2017
- MedStar Health/Georgetown-Washington HospitalResidency, Surgery, 2012 - 2015
- National Cancer InstituteFellowship, Complex General Surgical Oncology, 2009 - 2012
- Rutgers Health/St Barnabas Medical CenterResidency, Surgery, 2007 - 2009
- St. George's University School of MedicineClass of 2007
- Cornell UniversityBA, 1999 - 2003
Certifications & Licensure
- NJ State Medical License 2017 - 2025
- NY State Medical License 2015 - 2018
- DC State Medical License 2012 - 2016
- VA State Medical License 2011 - 2016
- MD State Medical License 2009 - 2012
- American Board of Surgery Surgery
- American Board of Surgery Complex General Surgical Oncology
Awards, Honors, & Recognition
- Medical Honoree, 40th Annual Diamond Ball American Cancer Society, 2019
- Fellow of the Society of Surgical Oncology 2017
- Fellow (FACS) American College of Surgeons
Publications & Presentations
PubMed
- Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer.Tomohiro M Ko, Kayla N Laraia, H Richard Alexander, Brett L Ecker, Miral S Grandhi
Surgery. 2024-09-01 - Operative trends for pancreatic and hepatic malignancies during the COVID-19 pandemic.Alexander Manzella, Brett L Ecker, Mariam F Eskander, Miral S Grandhi, Haejin In
Surgery. 2024-08-01 - ASO Visual Abstract: Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: A SEER Database Analysis of Mucinous and Non-mucinous Histologies.Vasileios Tsagkalidis, Jennie K Choe, Toni Beninato, Mariam F Eskander, Miral S Grandhi
Annals of Surgical Oncology. 2024-07-01
Journal Articles
- Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer...Mihir M Shah, Darren R Carpizo, Miral S Grandhi, Russell C Langan, Journal of The American College of Surgeons
Authored Content
- Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer DatabaseOctober 2018
Press Mentions
- Pancreatic Cancer Rates Are Spiking in Women 55 and Under. Experts Don’t yet Know WhyMay 11th, 2023
- What Causes Pancreatic Cancer and How Is It Treated?May 3rd, 2023
- Do Pancreatic Cysts Become Cancerous?November 1st, 2022
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: